Search

EPIC, an electronic medical record (EMR), has the capability for patients to enter their own data through the patient portal, MyChart. However, this function was not utilized. Intake specialists e-mailed paper intake forms, which were returned by fax and scanned into EPIC. The nurse coordinator (NC) also called patients, gathered data by phone, and manually entered it into the EMR. The purpose was to provide patients with an electronic form via MyChart to complete before their visit engaging them to actively participate in their own care. The project workflow was designed to save nursing, administration, and transcription time. An Epic Optimization request was placed to initiate a disease specific fillable form to be added to MyChart for New Patient Intake in the Breast Clinic of Women's Oncology Services. The NC collaborated with the nurse analyst from the EPIC team to develop the form and create a new workflow. They trained the clinical staff on how to access the information and reconcile the medical record. After the electronic forms were developed, the intake staff was trained and a physician champion was identified to pilot the project. A total of 20 female patients participated in the pilot; 13/20 (65%) were diagnosed with breast cancer and 7/20 (35%) had benign breast issues. The age range was from 33-86 with the mean age of 61. A total of 15/20 (75%) completed the two questionnaires. Participants' feedback included ease, speed and simplicity of form completion, and reduction of redundant paperwork. Team member comments revealed major time savings, efficiency, and security of patient information. More nursing time remained to support the patient. After the pilot project was complete, it was presented at breast center leadership and staff meetings. The nurse analyst and NC provided individual and group training for staff. Smart phrases were developed and shared with staff for data input into the EMR. A full roll out was implemented with plans to expand to other disease teams. This workflow fully utilizes the EMR and allows patients to participate in their own care. It ensures that the medical record is accurate, secures patient data, and reduces redundancy. The information can be re-viewed prior to the visit and the process saves valuable nursing time. [ABSTRACT FROM AUTHOR]

Purpose The 21-gene recurrence score (RS) assay is used to help formulate adjuvant chemotherapy recommendations for patients with estrogen receptor-positive, early-stage breast cancer. Most frequently, medical oncologists order RS after surgery. Results take an additional 2 weeks to return, which can delay decision making. We conducted a prospective qualityimprovement project to assess the impact of early guideline-directed RS ordering by surgeons before the first visit with a medical oncologist on adjuvant therapy decision making. Materials and Methods Surgical oncologists ordered RS testing following National Comprehensive Cancer Network guidelines at time of diagnosis or at time of surgery between July 1, 2015 and December 31, 2015. We measured the testing rate of patients eligible for RS, time to chemotherapy decisions, rates of chemotherapy use, accrual to RS-based clinical trials, cost, and physician acceptance of the policy and compared the results to patients who met eligibility criteria for early guideline-directed testing during the 6 months before the project. Results Ninety patients met eligibility criteria during the testing period. RS was ordered for 91% of patients in the early testing group compared with 76% of historical controls (P, .001). Median time to chemotherapy decision was significantly shorter in the early testing group (20 days; 95% CI, 17 to 23 days) compared with historical controls (32 days; 95% CI, 29 to 35 days; P, .001). There were no significant differences in time to chemotherapy initiation, chemotherapy use, RS-based trial enrollment, or calculated costs between the groups. Conclusion Early guideline-directed RS testing in selected patients is an effective way to shorten time to treatment decisions. [ABSTRACT FROM AUTHOR]